1)Matsubara A, Ogawa R, Suzuki H, et al. Activating GNAS and KRAS mutations in gastric foveolar metaplasia, gastric heterotopia, and adenocarcinoma of the duodenum. Br J Cancer 112:1398-1404, 2015
2)Minatsuki C, Yamamichi N, Inada KI, et al. Expression of gastric markers is associated with malignant potential of nonampullary duodenal adenocarcinoma. Dig Dis Sci 63:2617-2625, 2018
3)Mitsuishi T, Hamatani S, Hirooka S, et al. Clinicopathological characteristics of duodenal epithelial neoplasms:Focus on tumors with a gastric mucin phenotype(pyloric gland-type tumors). PLoS One 12:e0174985, 2017
4)Ushiku T, Arnason T, Fukayama M, et al. Extra-ampullary duodenal adenocarcinoma. Am J Surg Pathol 38:1484-1493, 2014
5)Fu T, Pappou EP, Guzzetta AA, et al. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res 18:4743-4752, 2012
6)Kumagai R, Kohashi K, Takahashi S, et al. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine. World J Gastroenterol 21:2700-2710, 2015
7)Laforest A, Aparicio T, Zaanan A, et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer 50:1740-1746, 2014
8)Overman MJ, Pozadzides J, Kopetz S, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102:144-150, 2010
9)Schrock AB, Devoe CE, McWilliams R, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol 3:1546-1553, 2017